Sofituzumab vedotin

Sofituzumab vedotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of a monoclonal antibody, sofituzumab, linked to a cytotoxic agent, vedotin. The antibody targets the protein nectin-4, which is overexpressed in several types of cancer, including bladder cancer, breast cancer, and lung cancer. The cytotoxic agent is then released into the cancer cell, causing cell death.

Mechanism of action

Sofituzumab vedotin works by targeting the protein nectin-4, which is overexpressed in several types of cancer. The monoclonal antibody, sofituzumab, binds to nectin-4 on the surface of cancer cells. The cytotoxic agent, vedotin, is then released into the cancer cell, causing cell death.

Clinical trials

Sofituzumab vedotin has been tested in several clinical trials for various types of cancer. In a phase I trial for patients with metastatic urothelial cancer, the drug showed promising results, with a response rate of 44%. A phase II trial for patients with metastatic breast cancer is currently ongoing.

Side effects

Common side effects of sofituzumab vedotin include fatigue, nausea, and decreased appetite. Serious side effects can include peripheral neuropathy, neutropenia, and skin reactions.

See also

• Antibody-drug conjugate
• Monoclonal antibody
• Cytotoxicity
• Nectin-4
• Clinical trial

Sofituzumab vedotin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski